Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of market exclusivity for Stelara. A strong medical technology segment and an …
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
view original post